% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Fangusaro:285301,
      author       = {J. Fangusaro and D. T. Jones$^*$ and R. J. Packer and D. H.
                      Gutmann and T. Milde$^*$ and O. Witt$^*$ and S. Mueller and
                      M. J Fisher and J. R. Hansford and U. Tabori and D. Hargrave
                      and P. Bandopadhayay},
      title        = {{P}ediatric low-grade glioma: {S}tate-of-the-art and
                      ongoing challenges.},
      journal      = {Neuro-Oncology},
      volume       = {26},
      number       = {1},
      issn         = {1522-8517},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {DKFZ-2023-02322},
      pages        = {25-37},
      year         = {2024},
      note         = {2024 Jan 5;26(1):25-37},
      abstract     = {The most common childhood central nervous system (CNS)
                      tumor is pediatric low-grade glioma (pLGG), representing
                      $30\%-40\%$ of all CNS tumors in children. Although there is
                      high associated morbidity, tumor-related mortality is
                      relatively rare. pLGG is now conceptualized as a chronic
                      disease, underscoring the importance of functional outcomes
                      and quality-of-life measures. A wealth of data has emerged
                      about these tumors, including a better understanding of
                      their natural history and their molecular drivers, paving
                      the way for the use of targeted inhibitors. While these
                      treatments have heralded tremendous promise, challenges
                      remain about how to best optimize their use, and the
                      long-term toxicities associated with these inhibitors remain
                      unknown. The International Pediatric Low-Grade Glioma
                      Coalition (iPLGGc) is a global group of physicians and
                      scientists with expertise in pLGG focused on addressing key
                      pLGG issues. Here, the iPLGGc provides an overview of the
                      current state-of-the-art in pLGG, including epidemiology,
                      histology, molecular landscape, treatment paradigms,
                      survival outcomes, functional outcomes, imaging response,
                      and ongoing challenges. This paper also serves as an
                      introduction to 3 other pLGG manuscripts on (1) pLGG
                      preclinical models, (2) consensus framework for conducting
                      early-phase clinical trials in pLGG, and (3) pLGG
                      resistance, rebound, and recurrence.},
      keywords     = {MAPK/ERK pathway (Other) / overview (Other) / pediatric
                      low-grade glioma (Other) / targeted therapy (Other)},
      cin          = {B360 / B310 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)B360-20160331 / I:(DE-He78)B310-20160331 /
                      I:(DE-He78)HD01-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37944912},
      doi          = {10.1093/neuonc/noad195},
      url          = {https://inrepo02.dkfz.de/record/285301},
}